| Zacks Company Profile for Guardant Health, Inc. (GH : NSDQ) |
|
|
| |
| • Company Description |
| Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Inc. is based in REDWOOD CITY, United States.
Number of Employees: 2,021 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $49.77 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,819,833 shares |
| Shares Outstanding: 123.89 (millions) |
| Market Capitalization: $6,165.91 (millions) |
| Beta: 1.44 |
| 52 Week High: $53.42 |
| 52 Week Low: $20.14 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
0.95% |
-2.84% |
| 12 Week |
16.80% |
-3.89% |
| Year To Date |
62.91% |
52.86% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Helmy Eltoukhy - Co-Chief Executive Officer and Chairman
Michael Bell - Chief Financial Officer
Ian Clark - Director
Vijaya Gadde - Director
Steve Krognes - Director
|
|
Peer Information
Guardant Health, Inc. (CORR.)
Guardant Health, Inc. (RSPI)
Guardant Health, Inc. (CGXP)
Guardant Health, Inc. (BGEN)
Guardant Health, Inc. (GTBP)
Guardant Health, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 40131M109
SIC: 8071
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/30/25
|
|
Share - Related Items
Shares Outstanding: 123.89
Most Recent Split Date: (:1)
Beta: 1.44
Market Capitalization: $6,165.91 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.78 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-3.21 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 6.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: 42.30% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 07/30/25 |
|
|
|
| |
